Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The distribution of carcinoembryonic antigen (CEA) in colorectal cancer (CRC) differs from that in normal colorectal tissue, being found on all borders of the cell membrane and hence enabling access to intravenous antibody, making CEA a good target for antibody-based therapy. The distinctive anti-CEA antibody, PR1A3, binds only membrane-bound CEA. Humanised PR1A3 (hPR1A3) was assessed both in vitro cytotoxicity and binding assays with colorectal cancer cell lines expressing varying levels of CEA. Human peripheral blood mononuclear cells (PBMCs) and purified natural killer (NK) cells were used as effectors. The in vitro assays demonstrated hPR1A3 CEA-specific binding and antibody-dependent and CEA-specific killing of human colorectal cancer cell lines by human PBMCs. The effect increased with increasing concentration of antibody and surface CEA, and was lost by using the parent murine IgG1 PR1A3. Killing was also blocked by antibody to the Fc-gammaIIIA receptor. Purified human NK cells were effective at much lower effector:target ratios than unfractionated PBMCs, indicating that NK cells were the main mediators of hPR1A3-based CEA-specific killing. The results support the development of hPR1A3 for therapy of colorectal cancer.

Original publication

DOI

10.1038/sj.bjc.6604289

Type

Journal article

Journal

Br J Cancer

Publication Date

08/04/2008

Volume

98

Pages

1217 - 1225

Keywords

Antibodies, Monoclonal, Antibodies, Neoplasm, Antibody Specificity, Antigen-Antibody Complex, Antigens, Neoplasm, Antigens, Surface, Carcinoembryonic Antigen, Cell Line, Tumor, Colorectal Neoplasms, Cytotoxicity, Immunologic, Drug Delivery Systems, Humans, Immunoglobulin Fab Fragments, Immunoglobulin G, Killer Cells, Natural, Receptors, IgG